Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01961921 · ClinicalTrials.gov registry record · Phase 2
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01961921 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT01961921, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
Interventions
- DRUG ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01961921
The ClinicalTrials.gov registry entry for NCT01961921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALN-TTR02 (patisiran) administered by intravenous (IV) infusion is the first listed.
NCT01961921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01961921 about?
NCT01961921 is a clinical study titled "The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)". The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
What is the current status of trial NCT01961921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2013-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01961921?
The interventions under investigation include: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion (DRUG).
Who is sponsoring clinical trial NCT01961921?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.